■2019年冠状病毒病(COVID-19)迅速传播,在全球夺走了数百万人的生命。急性呼吸窘迫综合征(ARDS)是COVID-19相关死亡的主要原因。由于目前药物的局限性,必须开发可在临床上快速安全地用于治疗严重急性呼吸道综合征冠状病毒-2(SARS-CoV-2)感染的有效治疗方案。本研究旨在探讨两种食物提取的免疫调节剂的作用,富含ajoene的大蒜提取物(AGE)和十字花科蔬菜提取的萝卜硫烷(SFN),SARS-CoV-2急性肺损伤小鼠模型的抗炎和免疫反应。
■在这项研究中,我们通过气管内注射聚肌苷酸:聚胞嘧啶酸(poly[I:C])和SARS-CoV-2重组刺突蛋白(SP),建立了模拟SARS-CoV-2感染急性肺损伤的小鼠模型。经过不同的药剂处理,肺切片,收集支气管肺泡灌洗液(BALF)和新鲜粪便。然后,H&E染色用于检查间质性肺炎的症状。流式细胞术用于检测免疫细胞群体的变化。采用多重细胞因子法检测炎性细胞因子;采用16SrDNA高通量测序法检测肠道微生物组的变化。
■我们的结果表明,AGE和SFN可以明显抑制间质性肺炎的症状,有效抑制炎症细胞因子的产生,降低了炎症细胞群体的百分比,和小鼠模型中T细胞群的升高。此外,我们还观察到,在AGE治疗组中,副细菌属的肠道微生物组富集.
■这里,第一次,我们观察到这两部小说,安全,和相对便宜的免疫调节剂对抗炎和免疫反应表现出相同的作用,作为抗白细胞介素6受体(IL-6R)的中和单克隆抗体(mAb),已被建议用于治疗COVID-19患者。我们的结果揭示了这两种免疫调节剂在SARS-CoV-2急性肺损伤小鼠模型中通过促进抗炎和免疫反应的治疗能力。这些结果表明,AGE和SFN是COVID-19治疗的有希望的候选药物。
UNASSIGNED: The coronavirus disease 2019 (COVID-19) spread rapidly and claimed millions of lives worldwide. Acute respiratory distress syndrome (ARDS) is the major cause of COVID-19-associated deaths. Due to the limitations of current drugs, developing effective therapeutic options that can be used rapidly and safely in clinics for treating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is necessary. This study aims to investigate the effects of two food-extracted immunomodulatory agents, ajoene-enriched garlic extract (AGE) and cruciferous vegetables-extracted sulforaphane (SFN), on anti-inflammatory and immune responses in a SARS-CoV-2 acute lung injury mouse model.
UNASSIGNED: In this study, we established a mouse model to mimic the SARS-CoV-2 infection acute lung injury model via intratracheal injection of polyinosinic:polycytidylic acid (poly[I:C]) and SARS-CoV-2 recombinant spike protein (SP). After the different agents treatment, lung sections, bronchoalveolar lavage fluid (BALF) and fresh faeces were harvested. Then, H&E staining was used to examine symptoms of interstitial pneumonia. Flow cytometry was used to examine the change of immune cell populations. Multiplex cytokines assay was used to examine the inflammatory cytokines.16S rDNA high-throughput sequencing was used to examine the change of gut microbiome.
UNASSIGNED: Our results showed that AGE and SFN significantly suppressed the symptoms of interstitial pneumonia, effectively inhibited the production of inflammatory cytokines, decreased the percentage of inflammatory cell populations, and elevated T cell populations in the mouse model. Furthermore, we also observed that the gut microbiome of genus Paramuribaculum were enriched in the AGE-treated group.
UNASSIGNED: Here, for the first time, we observed that these two novel, safe, and relatively inexpensive immunomodulatory agents exhibited the same effects on anti-inflammatory and immune responses as neutralizing monoclonal antibodies (mAbs) against interleukin 6 receptor (IL-6R), which have been suggested for treating COVID-19 patients. Our results revealed the therapeutic ability of these two immunomodulatory agents in a mouse model of SARS-CoV-2 acute lung injury by promoting anti-inflammatory and immune responses. These results suggest that AGE and SFN are promising candidates for the COVID-19 treatment.